LTF-001 is a long-term follow-up study of participants who received an investigational gene-editing therapy developed by Verve Therapeutics, designed to evaluate the long-term effects of that therapy. Participants are followed for a total of 15 years after the first administration of the gene-editing therapy. Enrollment is by invitation and open to people who completed or discontinued a Verve-sponsored study in which they received at least one dose of study drug and who provide informed consent for LTF-001.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria 1. A participant has completed or discontinued from a Verve sponsored clinical study in which they received at least one dose of study drug. 2. A participant has provided informed consent for LTF-001. Exclusion Criteria: N/A